Dr. Jonathan D. Graf, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 55
Licensed in California since 1999, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Perelman School of Med at the University of Pennsylvania
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
CA license A68479 (first issued 1999; current) -
Rheumatology Physician
CA license A68479 (first issued 1999; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Zuckerberg San Francisco General Hosp & Trauma Ctr San Francisco, CA
Medical groups
- University of California Sfgh Medical Group (587 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 55
- Services billed
- 190
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 103 | 35 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 61 | 25 |
| Hospital discharge day management, 30 minutes or less | 24 | 23 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 17 | 17 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in San Francisco, CA | 233 |
| Methotrexate (methotrexate sodium) Other prescribers in San Francisco, CA | 162 |
| Hydroxychloroquine Sulfate Other prescribers in San Francisco, CA | 81 |
| Sulfasalazine Other prescribers in San Francisco, CA | 75 |
| Cimzia (2 Pack) (certolizumab pegol) | 70 |
| Humira Pen (adalimumab) Other prescribers in San Francisco, CA | 58 |
| Alendronate Sodium Other prescribers in San Francisco, CA | 58 |
| Enbrel Sureclick (etanercept) Other prescribers in San Francisco, CA | 48 |
| Leflunomide Other prescribers in San Francisco, CA | 45 |
| Meloxicam Other prescribers in San Francisco, CA | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $153 in total to this clinician.
| Janssen Biotech, Inc. | $99.99 |
|---|---|
| Genentech, Inc. | $53.45 |
| Education | $153 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Jun 11, 2025 | Education TREMFYA · Immunology · in-kind | $99.99 |
| Genentech, Inc. Mar 16, 2025 | Education in-kind | $53.45 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $72,530 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.